A PHASE I CONCENTRATION-CONTROLLED TRIAL TO ASSESS THE SAFETY, TOLERANCE, PHARMACOKINETICS AND DEVELOPMENT OF DECREASED HIV-1 SUSCEPTIBILITY TO THE COMBINATION OF ATEVIRDINE MESYLATE (U-87201E), ZIDOVUDINE (AZT), AND DIDANOSINE (DDI):